These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 9352708)
1. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Herr HW Br J Urol; 1997 Oct; 80(4):653-7. PubMed ID: 9352708 [TBL] [Abstract][Full Text] [Related]
2. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Aprikian AG; Herr HW; Bajorin DF; Bosl GJ Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456 [TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses. Nakamura T; Oishi M; Ueda T; Fujihara A; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T Int J Urol; 2015 Jul; 22(7):663-8. PubMed ID: 25847721 [TBL] [Abstract][Full Text] [Related]
4. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. Beck SD; Foster RS; Bihrle R; Ulbright T; Koch MO; Wahle GR; Einhorn LH; Donohue JP J Urol; 2002 Oct; 168(4 Pt 1):1402-4. PubMed ID: 12352402 [TBL] [Abstract][Full Text] [Related]
5. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study. Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263 [TBL] [Abstract][Full Text] [Related]
6. Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis. Nitta S; Kawai K; Kimura T; Kandori S; Kawahara T; Kojima T; Nishiyama H Int J Urol; 2021 Aug; 28(8):840-847. PubMed ID: 34085325 [TBL] [Abstract][Full Text] [Related]
7. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? Rabbani F; Goldenberg SL; Gleave ME; Paterson RF; Murray N; Sullivan LD Br J Urol; 1998 Feb; 81(2):295-300. PubMed ID: 9488075 [TBL] [Abstract][Full Text] [Related]
8. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. Fosså SD; Aass N; Ous S; Høie J; Stenwig AE; Lien HH; Paus E; Kaalhus O J Urol; 1989 Nov; 142(5):1239-42. PubMed ID: 2478726 [TBL] [Abstract][Full Text] [Related]
10. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements. Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394 [TBL] [Abstract][Full Text] [Related]
11. Testicular tumors: residual retroperitoneal mass surgery after chemotherapy;Is it possible to predict their histology? Medina-Polo J; Martínez-Silva V; Domínguez-Esteban M; de la Rosa-Kehrmann F; Villacampa-Aubá F; Castellano-Gauna D; Díaz-González R Arch Esp Urol; 2011 Sep; 64(7):611-9. PubMed ID: 21965259 [TBL] [Abstract][Full Text] [Related]
13. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Hartmann JT; Candelaria M; Kuczyk MA; Schmoll HJ; Bokemeyer C Eur J Cancer; 1997 May; 33(6):843-7. PubMed ID: 9291803 [TBL] [Abstract][Full Text] [Related]
17. [A case of teratoma of the testis with retroperitoneal lymph nodes involved with malignant teratoma after chemotherapy]. Muraki J; Nakazono M Nihon Hinyokika Gakkai Zasshi; 1993 Dec; 84(12):2162-5. PubMed ID: 7508531 [TBL] [Abstract][Full Text] [Related]
18. Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study. Miranda Ede P; Abe DK; Nesrallah AJ; dos Reis ST; Crippa A; Srougi M; Dall'Oglio MF World J Surg Oncol; 2012 Sep; 10():203. PubMed ID: 23021209 [TBL] [Abstract][Full Text] [Related]
19. Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting. Considine S; Heaney R; Conroy R; Thornhill JA Ir J Med Sci; 2016 Nov; 185(4):901-907. PubMed ID: 26692387 [TBL] [Abstract][Full Text] [Related]
20. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]